OMedLive

CME Presentations

Bladder Cancer


Presentations

  • CME
    1.0

    New Horizons in Personalized Care for Metastatic Bladder Cancer

    Speakers:Matthew I. Milowsky, MD, Section Chief, Genitourinary Oncology
    Matthew Galsky, MD, Director of Genitourinary Medical Oncology

    Duration: 60 minutes

    Presented on: August 11, 2017


Speakers

  • Matthew I. Milowsky, MD

    Matthew I. Milowsky, MD

    Matthew I. Milowsky, MD

    Section Chief, Genitourinary Oncology

    Matthew I. Milowsky, MD, is section chief of the Genitourinary Oncology Service and co-director of the Urologic Oncology Program at the University of North Carolina (UNC) at Chapel Hill Lineberger Comprehensive Cancer Center. He leads the Genitourinary Oncology Research Program, which focuses on translational science and clinical trials for patients with urologic cancers. Dr Milowsky is also the clinic medical director at North Carolina Cancer Hospital, where he serves as a member of the Executive Committee and co-chair of the Operations Committee. He has published extensively in peer-reviewed journals, written several book chapters, and was principal investigator on the American Association for Cancer Research Henry Shepard Grant for Bladder Cancer Research.
  • Matthew Galsky, MD

    Matthew Galsky, MD

    Matthew Galsky, MD

    Director of Genitourinary Medical Oncology

    Matthew Galsky, MD, is the director of genitourinary medical oncology at the Mount Sinai School of Medicine Tisch Cancer Institute in New York. Dr Galsky specializes in caring for patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the clinical development of novel therapies for genitourinary cancers, with a particular emphasis on bladder cancer, and he regularly speaks nationally and internationally on the topic. His research has been published in numerous journals, including the Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology and Lancet, and has been funded by organizations that include the National Institutes of Health/National Cancer Institute and the Department of Defense.

CME Information

New Horizons in Personalized Care for Metastatic Bladder Cancer

Presented by the Albert Einstein College of Medicine and Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC

 

ACKNOWLEDGEMENT This activity is supported by an independent educational grant from Genentech, Inc.

TUITION Complimentary

ACCREDITATION STATEMENT The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Internet Activity Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION Live Internet Activity Friday, August 11, 2017 from 11:00 AM EST – 12:00 PM EDT Enduring Material The enduring material will be available from August 11, 2017 to February 11, 2018.

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Evaluate the role of new targeted and immune-based agents in the first- and second-line metastatic settings, and how they can be integrated into practice
Apply strategies and tools that enhance patient-clinician communication and shared decision making processes
 

INTENDED AUDIENCE Medical/genitourinary oncologists, urologists, surgeons, radiologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with bladder cancer.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters Disclosures
Matthew Galsky, MD

Consultant: AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Inc. Contracted Research: Bristol-Myers Squibb, Merck & Co.

Matthew I. Milowsky, MD

Contracted Research: AstraZeneca/MedImmune, BioClin Therapeutics, Inc., Bristol-Myers Squibb, Genentech, Inc., Merck & Co., Pfizer, Inc.

 

Peer Reviewer Disclosures
Jesus Anampa Mesias, MD Has nothing to disclose relevant to this activity.
Providers Disclsoures
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
 

PlatformQ Health Education, LLC Disclsoures
Hamsa Jaganathan, Medical Director Has nothing to disclose relevant to this activity
Elizabeth del Nido, Program Manager Has nothing to disclose relevant to this activity.
 

CONTACT INFORMATION Accreditation Support: Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

Technical Support: For issues with your CME Certificate, please contact OMedLive at 877–394–1306 or at Support@OMedLive.com

DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.